scholarly journals Aqueous Extract of Fagara tessmannii Engl. (Rutaceae) Exhibits Antihypertensive Activity in NO Synthase Inhibitor-Induced Hypertensive Rats

2020 ◽  
pp. 1-9
Author(s):  
Théophile Dimo ◽  
Yannick Bekono Fouda ◽  
Esther Ngo Lemba Tom ◽  
Bibi-Farouck Aboubakar Oumarou ◽  
Lohik Nguegang Mbolang ◽  
...  
Keyword(s):  
Heart Rate ◽  
Endothelial Dysfunction ◽  
Aqueous Extract ◽  
Heart Function ◽  
Heart Diseases ◽  
Hdl Cholesterol ◽  
Modern Medicine ◽  
Risk Indicators ◽  
Antihypertensive Activity ◽  
Induced Hypertension

Background: Most cardiovascular troubleshot ultimately result of endothelial dysfunction-induced hypertension, an intractable problem in modern medicine. Fagara tessmannii, a shrub of the African rainforests found in Cameroon is traditionally used to treat heart diseases and hypertension. This study aimed to evaluate the preventive effects of the aqueous extract of F. tessmannii (AEFT) on arterial hypertension induced by NG-Nitro-L-arginine-methyl ester (L-NAME). Methods: Male Wistar rats received saline (5 mL.kg-1 , intraperitoneally) or L-NAME (25 mg.kg-1 ; intraperitoneally), L-NAME + AEFT (100 or 200 mg.kg-1 ; orally) or captopril (20 mg.kg-1 ; orally) for three weeks. Then, blood and pulse pressures (BP and PP), heart rate, lipid profile, kidney, liver and heart function markers and oxidative status were evaluated. Results: AEFT (100 and 200 mg.kg-1 ) prevented the increase in BP (p < 0.001), PP (p < 0.01), and heart rate (p < 0.05) induced by L-NAME. The extract has suppressed the decline of weight gain, visceral fat and triglyceridemia, decreased total cholesterol, increased HDL-cholesterol, and significantly reduced (p < 0.001) atherogenic and coronary risk indicators. AEFT also improved the liver, kidney and heart markers, nitrites levels and prevented TBARS enhancement as compared to the hypertensive group. The remodeling of the media and fibrosis process in coronaries were also prevented by the extract. Conclusion: These results suggest that AEFT can prevent endothelial dysfunction-induced hypertension, dyslipidemia and associated atherogenic risks, and oxidative stress induced by L-NAME.

scholarly journals Aqueous extract of Pterocarpus santalinoides DC stem bark prevents L-NAME-induced hypertension in rat

2021 ◽  
Vol 10 (3) ◽  
pp. 166-172
Author(s):  
Chinte Yamjom Ramatou ◽  
◽  
Ngo Lemba Thom Esther ◽  
Florence Tsofack Ngueguim ◽  
Yannick Bekono Fouda ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Heart Rate ◽  
Aqueous Extract ◽  
Hdl Cholesterol ◽  
Experimental Period ◽  
Stem Bark ◽  
Renal Markers ◽  
Induced Hypertension ◽  
And Oxidative Stress ◽  
Pterocarpus Santalinoides

Background: Pterocarpus santalinoides stem bark is commonly used in Cameroonian medicine to treat many diseases including hypertension. Thus, this study was aimed to evaluate preventive effects of aqueous extract of Pterocarpus santalinoides (AEPS) stem bark on NG-Nitro-L-arginine-methyl ester (LNAME)-induced hypertension in rat. Methods: Normotensive rats received L-NAME (25 mg/kg intraperitoneally) concomitantly with AEPS (50, 100 and 200 mg/kg) or captopril (20 mg/kg) orally during 3 weeks. At the end of experimental period, arterial pressure and heart rate were recorded by invasive method. After sacrifice, blood, aorta and heart were harvested for biochemical analysis on homogenate. Results: Intraperitoneal injection of L-NAME induced in rat a significant increase (p < 0.001; p < 0.01; p < 0.05) of blood pressure, heart rate, malondialdehyde, total cholesterol, triglycerides, LDL-cholesterol, hepatic and renal markers functions. L-NAME also decreased significantly (p < 0.001; p < 0.01; p < 0.05) the levels of HDL-cholesterol, nitrites, glutathione, superoxide dismutase and catalase activities as compared to control rats. The AEPS prevented significantly the increase (p < 0.001) of hemodynamic parameters induced by L-NAME and various modifications of biochemical parameters (lipid profile, hepatic and renal markers functions) and oxidative stress markers evaluated. Conclusion: This study shows that the aqueous extract of Pterocarpus santalinoides prevents hypertension, dyslipidemia and oxidative stress induced by L-NAME in rat by attenuating endothelial dysfunction, liver and kidney’s damages

scholarly journals Cissus quadrangularis Aqueous Extract Attenuates Angiotensin II-Induced Hypertension In Urethane-Anesthetized Rats

2021 ◽  
Vol 14 (4) ◽  
pp. 1459-1462
Author(s):  
Faiyaz Ahmed
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Angiotensin Ii ◽  
Aqueous Extract ◽  
Antihypertensive Activity ◽  
Intravenous Route ◽  
Ang Ii ◽  
Arterial Blood ◽  
Cissus Quadrangularis ◽  
Induced Hypertension

Hypertension is a major cardiovascular problem resulting in significant mortality. Cissus quadrangularis having several pharmacological effects has not been evaluated for its ability to modulate blood pressure. Thus, the ability of C. quadrangularis aqueous extract (CQE) to modulate blood pressure was evaluated in normotensive and angiotensin II-induced hypertensive rats under urethane anesthesia. The animals were divided into four groups namely, control (saline injection), CQE (extract alone, 10 mg/kg), Ang II (Ang II alone, 0.5 µg/kg) and Ang II + CQE (Ang II + extract). All treatments were delivered by intravenous route and in Ang II + CQE group, Ang II was injected 30 min after injection of the extract. Hemodynamic parameters, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MABP), and heart rate (HR) were recorded by the BIOPAC system after the cannulation of the carotid artery and jugular vein. The results indicated that CQE lowered SBP, DBP, MABP and heart rate to varying degrees in normotensive rats compared to control groups. In case of angiotensin II-induced hypertension, CQE administration resulted in substantial decrease in SBP, DBP, and MABP which were raised by Ang II. CQE reduced SBP, DBP, and MABP by 12, 59, and 11%, respectively. It is worth noting that, while SBP was not brought down to baseline levels by CQE, DBP was, suggesting significant hypotensive/antihypertensive activity of CQE. Further research is required to determine the molecular mechanism of C. quadrangularis extract’s hypotensive/antihypertensive action and to conduct clinical trials to establish its optimal use as an antihypertensive therapeutic.

Ruta montana evokes antihypertensive activity through increase of prosta-glandins release in L-NAME-induced hypertensive rats

2020 ◽  
Vol 20 ◽  
Author(s):  
El-Ouady Fadwa ◽  
Mohamed Eddouks
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Aqueous Extract ◽  
Antihypertensive Effect ◽  
Antihypertensive Activity ◽  
Computer Assisted ◽  
Hypertensive Rats ◽  
Vasorelaxant Effect ◽  
Vasorelaxant Activity ◽  
Ruta Montana

Aims: The aim of the study was to investigate experimentally the antihypertensive effect of Ruta Montana. Background: Ruta montana L. is traditionally used in Moroccan herbal medicine to treat hypertension. This study aimed to evaluate experimentally the hypotensive and vasoactive properties of this plant. Objective: The objective of the study was to evaluate the effect of the aqueous extract of Ruta Montana on blood pressure parameters in LNAME-induced hypertensive rats and to determine the vasorelaxant activity of this aqueous extract. Methods: The antihypertensive effect of the aqueous extract obtained from Ruta montana aerial parts (RMAPAE) (200 mg/kg) was evaluated in normal and anesthetized hypertensive rats. Blood pressure parameters (systolic blood pressure (SBP), mean blood pressure (MBP) and diastolic blood pressure (DBP)) and heart rate were measured using a tail-cuff and a computer-assisted monitoring device. The acute and chronic effect of RMAPAE was recorded during 6 hours for the acute experiment and during 7 days for the sub-chronic test. In the other set, the vasorelaxant effect of RMAPAE on the contractile response was undertaken in isolated thoracic aorta. Results: The results indicated that RMAPAE extract significantly decreased SBP, MBP, DBP and heart rate in L-NAMEinduced hypertensive rats. Furthermore, RMAPAE was demonstrated to induce a dose dependent relaxation in the aorta precontracted with Epinephrine or KCl. More interestingly, this vasorelaxant activity of RMAPAE seems to be probably mediated through the prostaglandins pathway. Conclusion: The present study illustrates the beneficial action of Ruta montana on hypertension and supports then its use as an antihypertensive agent.

scholarly journals Allablanckia floribunda hypotensive activity on ethanol induced hypertension in rats

2018 ◽  
Vol 7 (2) ◽  
pp. 146-151
Author(s):  
Danielle Claude Bilanda ◽  
◽  
Paul Désiré Djomeni Dzeufiet ◽  
Orelien Mtopi Bopda ◽  
Pierre Kamtchouing ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Aqueous Extract ◽  
Plant Extract ◽  
Colorimetric Method ◽  
Antioxidant Properties ◽  
Radical Scavenging ◽  
Hdl Cholesterol ◽  
Hypotensive Activity ◽  
Hypertensive Rats ◽  
Induced Hypertension

Background: Chronic alcohol intake is related to hypertension. In the present work, we investigated the effect of Allablanckia floribunda Oliver (Clusiaceae) aqueous extract in alcohol-induced hypertensive rats and on related oxidative stress damages. Methods: Alcohol-induced hypertensive rats (AHR) was obtained by oral administration of ethanol (3 g/kg/day during 8 weeks). Blood pressure and heart rate were evaluated using the direct cannulation method. The effects of the extract on lipid profile as well as kidney and liver functions were studied. Free radical scavenging and antioxidant properties of the extract were evaluated by colorimetric method. The effects of A. floribunda were evaluated after 4 weeks of treatment with alcohol. Results: At the doses of 200 and 400 mg/kg/day, A. floribunda significantly decreased the mean blood pressure of AHR by 14.06 and 23.25 % respectively. Administration of the plant extract lead to the reduction of total cholesterol by 41.50% and 43.06%, HDL-cholesterol by 22.16 and 30.15% and artherogenic index by 69.78 and 74.43%, respectively at the doses of 200 and 400 mg/kg, as compared to untreated hypertensive rats. A. floribunda (200 and 400 mg/kg) decrease bilirubine (12.98 and 16.88%), urea (23.32% and 32.26 %), ALT (10.73 and 27.97%) and AST (29.80 and 42.22%) of treated AHR, respectively. The plant extract also reduced superoxide dismutase (SOD), malondialdehyde (MDA) and catalase and increased the reduced glutathione (GSH) concentration in aorta, heart, kidney and liver of AHR. Conclusion: These results suggest that the aqueous extract of A. floribunda possesses antioxidant and hypotensive activity in alcohol-induced hypertension

scholarly journals Vasorelaxant-Mediated Antihypertensive Effect of the Leaf Aqueous Extract from Stephania abyssinica (Dillon & A. Rich) Walp (Menispermaceae) in Rat

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Chamberlin Fodem ◽  
Elvine Pami Nguelefack-Mbuyo ◽  
Magloire Kanyou Ndjenda II ◽  
Albert Kamanyi ◽  
Télesphore Benoit Nguelefack
Keyword(s):  
Nitric Oxide ◽  
Heart Rate ◽  
Methylene Blue ◽  
Aqueous Extract ◽  
Calcium Release ◽  
Inhibitory Effect ◽  
Antihypertensive Activity ◽  
Phytochemical Analysis

Stephania abyssinica is a medicinal plant used in Cameroon alternative medicine to treat arterial hypertension (AHT). Previous in vitro studies demonstrated the endothelium nitric oxide-independent vasorelaxant property of the aqueous extract from Stephania abyssinica (AESA). But its effect on AHT is unknown. The present study was undertaken to explore other vasorelaxant mechanisms and to determine the antihypertensive effects of AESA in male Wistar rats. Phytochemical analysis of AESA was carried out using the liquid chromatography-mass spectrometry (LC-MS) method. The vasorelaxant effects of AESA (1-1000 μg/mL) were studied on rat isolated thoracic aorta rings, in the absence or presence of indomethacin (10 μM) or methylene blue (10 μM). The inhibitory effect of AESA on phenylephrine (PE, 10 μM) or KCl- (60 mM) induced contraction as well as the intracellular calcium release was also evaluated. The in vivo antihypertensive activity of AESA (43, 86, or 172 mg/kg/day) or captopril (20 mg/kg/day) administered orally was assessed in L-NAME- (40 mg/kg/day) treated rats. Blood pressure and heart rate (HR) were measured at the end of each week while serum or urinary nitric oxide (NO), creatinine, and glomerular filtration rate (GFR) were determined at the end of the 6 weeks of treatment, as well as histological analysis of the heart and the kidney. The LC-MS profiling of AESA identified 9 compounds including 7 alkaloids. AESA produced a concentration-dependent relaxation on contraction induced either by PE and KCl, which was significantly reduced in endothelium-denuded vessels, as well as in vessels pretreated with indomethacin and methylene blue. Moreover, AESA inhibited the intracellular Ca2+ release-induced contraction. In vivo, AESA reduced the AHT, heart rate (HR), and ventricular hypertrophy and increased serum NO, urine creatinine, and GFR. AESA also ameliorated heart and kidney lesions as compared to the L-NAME group. These findings supported the use of AESA as a potential antihypertensive drug.

scholarly journals Antihypertensive Activity of Leersia hexandra Sw. (Poaceae) Aqueous Extract on Ethanol-Induced Hypertension in Wistar Rat

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Danielle Claude Bilanda ◽  
Yannick Carlos Tcheutchoua ◽  
Paul Désiré Djomeni Dzeufiet ◽  
Daniel Lauré Dongmo Fokou ◽  
Yannick Bekono Fouda ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Aqueous Extract ◽  
Antioxidant Activities ◽  
Hdl Cholesterol ◽  
Wistar Rat ◽  
Atherogenic Index ◽  
Antihypertensive Activity ◽  
Distilled Water ◽  
Hypertensive Rats ◽  
Leersia Hexandra

Leersia hexandra (L. hexandra) is used in traditional medicine to treat many diseases including hypertension. This study aimed to evaluate the curative effects of the aqueous extract of L. hexandra on hypertension. Hypertension was induced in rats by oral administration of ethanol (5 g/kg/day) for five weeks. The animals were divided into 2 groups: one group of 5 rats receiving distilled water (10 mL/kg) and another group of 20 rats receiving ethanol. At the end of the 5 weeks of administration of ethanol, the animals were divided into 4 groups of 5 rats each: one group of hypertensive rats receiving distilled water (10 mL/kg), another one receiving nifedipine (10 mg/kg), and two groups of hypertensive rats receiving L. hexandra at doses of 100 and 200 mg/kg, respectively. The results showed that ethanol induced a significant increase in the mean arterial pressure (MAP) and heart rate of normotensive rats. The administration of the extract (100 and 200 mg/kg) or nifedipine caused a significant decrease of MAP compared to hypertensive rats. Ethanol induced a significant increase of lipid profile, the atherogenic index, creatinine, and transaminase activities. Ethanol also induced a significant decrease in serum HDL-cholesterol and antioxidant markers evaluated. Treatment of hypertensive rats with L. hexandra or nifedipine significantly improved lipid profile, hepatic and renal functions, and antioxidant status. The curative effect of L. hexandra extract on hypertension is probably related to its antihypertensive, hypolipidemic, and antioxidant activities, which justifies its empirical use in the treatment of hypertension.

Effects of the Tibetan herbal preparation PADMA 28 on blood lipids and lipid oxidisability in subjects with mild hypercholesterolaemia

VASA ◽  
2005 ◽  
Vol 34 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Brunner-La Rocca ◽  
Schindler ◽  
Schlumpf ◽  
Saller ◽  
Suter
Keyword(s):  
Endothelial Dysfunction ◽  
Blood Lipids ◽  
Ex Vivo ◽  
Hdl Cholesterol ◽  
Blood Lipid ◽  
Tibetan Medicine ◽  
Double Blind ◽  
Intraarterial Infusion ◽  
Padma 28

Background: Previous studies showed an anti-atherosclerotic effect of PADMA 28, an herbal formula based on Tibetan medicine. As the mechanisms of action are not fully understood, we investigated whether PADMA 28 may lower blood lipids and lipid oxidisability, and affect early endothelial dysfunction. Patients and methods: Sixty otherwise healthy subjects with total cholesterol ≥5.2 mmol/l and < 8.0 mmol/l were randomly assigned to placebo or PADMA 28, 3 x 2 capsules daily, for 4 weeks (double-blind). Blood lipids (total, LDL-, and HDL-cholesterol, triglycerides, Apo-lipoprotein A1 and B) and ex vivo lipid oxidisability were measured before and after treatment. In a subset of 24 subjects, endothelial function was assessed using venous occlusion plethysmography with intraarterial infusion of acetylcholine. Isolated LDL and plasma both untreated and pre-treated with PADMA 28 extract were oxidised by the radical generator AAPH. Conjugated diene formation was measured at 245 nm. Results: Blood lipids did not change during the study in both groups. In contrast to previous reports in mild hypercholesterolaemia, no endothelial dysfunction was seen and, consequently, was not influenced by therapy. Ex vivo blood lipid oxidisability was significantly reduced with PADMA 28 (area under curve: 5.29 ± 1.62 to 4.99 ± 1.46, p = 0.01), and remained unchanged in the placebo group (5.33 ± 1.88 to 5.18 ± 1.78, p > 0.1). This effect persisted one week after cessation of medication. In vitro experiments confirmed the prevention of lipid peroxidation in the presence of PADMA 28 extracts. Persistent protection was also seen for LDL isolated from PADMA 28-pretreated blood after being subjected to rigorous purification. Conclusions: This study suggests that the inhibition of blood lipid oxidisability by PADMA 28 may play a role in its anti-atherosclerotic effect.

Effect of amiodarone on heart rate variability in patients with newly diagnosed atrial fibrillation (clinical observation)

2020 ◽  
pp. 81-85
Author(s):  
E. P. Popova ◽  
O. T. Bogova ◽  
S. N. Puzin ◽  
D. A. Sychyov ◽  
V. P. Fisenko
Keyword(s):  
Atrial Fibrillation ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Drug Therapy ◽  
Heart Function ◽  
Newly Diagnosed ◽  
Class Iii ◽  
Spectral Parameters ◽  
Patient Will ◽  
The Individual

Spectral analysis of heart rate variability gives an idea of the role of the autonomic nervous system in the regulation of chronotropic heart function. This method can be used to evaluate the effectiveness of drug therapy. Drug therapy should be carried out taking into account the individual clinical form of atrial fibrillation. Information about the vegetative status of the patient will undoubtedly increase the effectiveness of treatment. In this study, spectral parameters were studied in patients with newly diagnosed atrial fibrillation. The effect of antiarrhythmic drug class III amiodarone on the spectral parameters of heart rate variability was studied.

HEART COMPLICATIONS IN HYPERTHYROIDISM

2011 ◽  
pp. 7-17
Author(s):  
Hai Thuy Nguyen ◽  
Anh Vu Nguyen
Keyword(s):  
Atrial Fibrillation ◽  
Blood Pressure ◽  
Heart Rate ◽  
Heart Diseases ◽  
Systolic Dysfunction ◽  
Oxygen Demand ◽  
Left Ventricular ◽  
Cardiac Contraction ◽  
Cardiac Complications ◽  
Cardiac Symptoms

Thyroid hormone increases the force of the contraction and the amount of the heart muscle oxygen demand. It also increases the heart rate. Due to these reasons, the work of the heart is greatly increased in hyperthyroidism. Hyperthyroidism increases the amount of nitric oxide in the intima, lead them to be dilated and become less stiff. Cardiac symptoms can be seen in anybody with hyperthyroidism, but can be particularly dangerous in whom have underlying heart diseases. Common symptoms include: tachycardia and palpitations. Occult hyperthyroidism is a common cause of an increased heart rate at rest and with mild exertion. Hyperthyroidism can also produce a host of other arrhythmias such as PVCs, ventricular tachycardia and especially atrial fibrillation. Left ventricular diastolic dysfunction and systolic dysfunction, Mitral regurgitation and mitral valve prolapsed are heart complications of hyperthyroism could be detected by echocardiography. The forceful cardiac contraction increases the systolic blood pressure despite the increased relaxation in the blood vessels reduces the diastolic blood pressure. Atrial fibrillation, atrial enlargement and congestive heart failure are important cardiac complications of hyperthyroidism. An increased risks of stroke is common in patients with atrial fibrillation. Graves disease is linked to autoimmune complications, such as cardiac valve involvement, pulmonary arterial hypertension and specific cardiomyopathy. Worsening angina: Patients with coronary artery disease often experience a marked worsening in symptoms with hyperthyroidism. These can include an increase in chest pain (angina) or even a heart attack.

Sign in / Sign up

Export Citation Format

Share Document